Litcius/Paper detail

GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use

Mandana Haack‐Sørensen, Ellen Mønsted Johansen, Lisbeth Drozd Højgaard, Jens Kastrup, Annette Ekblond

2022Stem Cells International21 citationsDOIOpen Access PDF

Abstract

The emerging field of advanced therapy medicinal products (ATMP) holds promise of treating a variety of diseases. Adipose-derived stromal cells (ASCs) are currently being marketed or tested as cell-based therapies in numerous clinical trials. To ensure safety and efficacy of treatments, high-quality products must be manufactured. A good manufacturing practice (GMP) compliant and consistent manufacturing process including validated quality control methods is critical. Product design and formulation are equally important to ensure clinical feasibility. Here, we present a GMP-compliant, xeno-free, and semiautomated manufacturing process and quality controls, used for large-scale production of a cryopreserved off-the-shelf ASC product and tested in several phase I and II allogeneic clinical applications.

Topics & Concepts

Product (mathematics)Good manufacturing practiceClinical trialMedicineQuality (philosophy)CryopreservationClinical PracticeAdipose tissueCritical quality attributesBiotechnologyNew product developmentBusinessBiologyPathologyInternal medicineMathematicsCell biologyPhilosophyGeometryFamily medicineEmbryoMarketingEpistemologyRegulatory affairsMesenchymal stem cell researchPluripotent Stem Cells ResearchCAR-T cell therapy research
GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use | Litcius